GlassScriptPhysician profile
Marc C Gittelman
NPI 1174587604
$22,205.34
in general payments reported to CMS, 2019-2025
33 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,691 · 2021: $1,396 · 2022: $330 · 2023: $663 · 2024: $216 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,731.24 | 2019 | |
| Clarus Therapeutics INC. | $3,550.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $1,100.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $563.21 | 2021-2025 | Prolaris |
| Astellas Pharma US INC | $495.90 | 2019-2023 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $336.94 | 2019-2024 | Erleada |
| Becton, Dickinson and Company | $245.95 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Endo Pharmaceuticals INC. | $198.53 | 2019-2023 | Xiaflex |
| Boston Scientific Corporation | $158.92 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Abbvie INC. | $146.33 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $114.54 | 2020-2022 | |
| Pfizer INC. | $66.14 | 2022-2025 | |
| Coloplast Corp | $65.87 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $63.89 | 2019 | |
| Verity Pharmaceuticals INC. | $60.00 | 2023-2025 | Trelstar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $48.22 | 2022-2025 | Welireg, Keytruda |
| Sumitomo Pharma America, INC. | $42.26 | 2023-2024 | Gemtesa |
| Olympus America INC. | $32.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.87 | 2023 | |
| Sun Pharmaceutical Industries INC. | $23.59 | 2019 | |
| Endo USA, INC. | $22.56 | 2024 | Xiaflex |
| Halozyme INC | $19.49 | 2023 | |
| Tolmar, INC. | $19.20 | 2025 | Eligard, Jatenzo |
| Laborie Medical Technologies Corp. | $15.76 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $15.11 | 2019 | |
| Mission Pharmacal Company | $15.05 | 2019 | |
| Angiodynamics, INC. | $14.67 | 2022 | |
| Amniox Medical, INC. | $13.82 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Gittelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.